Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CEO post at Genevant
→ Gurnet Point Capital-backed Auregen BioTherapeutics has tapped Amgen vet Richard Davies to lead its rare disease cell therapy’s entry into the clinic as CEO. Davies, a former Hospira chief commercial officer who had his first chief executive experience recently at Bonesupport, will lead the drive in translating the Geneva-based biotech’s 3D biofabrication technologies to new therapeutics, starting from a program in rare congenital craniofacial disorders.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.